Morgan Stanley

Analysts at Morgan Stanley no longer hold a bearish view of Paychex, Inc. (NASDAQ: PAYX) after the stock's 19 percent year-to-date underperformance compared to the S&P 500's track has created a more "balanced" risk to reward profile. Morgan Stanley's Danyal Hussain upgrades Paychex's stock...

Morgan Stanley analyst Joseph Moore recently attended the 2017 Flash Memory Summit and took place in company events, panel discussions and private events with industry insiders. Following the summit, Moore is even more convinced of Morgan Stanley’s bullish thesis on Micron Technology, Inc. (...

Tesla Inc's (NASDAQ: TSLA) Model 3 announcement is shaping up to be one of the biggest catalysts in the company’s history. After updating its model to include an increased Model 3 unit forecast, Morgan Stanley increased its price target on Tesla from $305 to $317, still below current...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s management recently made the difficult decision to slash the company’s 6.5-percent dividend by 75 percent, lowering the stock’s yield to just 1.2 percent. The decision will save the company some much-needed cash, but it has done a...

The preliminary success of a drug designed to combat idiopathic pulmonary fibrosis could give Galapagos NV (ADR) (NASDAQ: GLPG) a 10-percent boost, according to Morgan Stanley. A 23-person study of the drug GLPG1690, an autotaxin inhibitor, found that patients had better lung function than those...

Pre-open movers U.S. stock futures traded lower in early pre-market trade, ahead of earnings from Macy's Inc (NYSE: M) and Kohl's Corporation (NYSE: KSS). Nordstrom, Inc. (NYSE: JWN) and NVIDIA Corporation (NASDAQ: NVDA) will release earnings after the closing bell. Data on initial jobless...

Morgan Stanley said in a note Tuesday it would be buyers of Clovis Oncology Inc (NASDAQ: CLVS) and TESARO Inc (NASDAQ: TSRO) ahead of the Lynparza label decision. AstraZeneca plc (ADR) (NYSE: AZN)'s Lynparza is a poly polymerase, or PARP, inhibitor indicated for use as a monotherapy in patients...

Defense stocks have been on a tear in recent years, but there may be even more upside ahead. On Wednesday, Morgan Stanley analyst Rajeev Lalwani said global threats aren’t going away anytime soon, and defense budgets keep expanding. Headlines about North Korea, Russia and the Middle East will...

Foot Locker Inc. (NYSE: FL)'s recent woes may provide a good buying opportunity at current depressed levels. Last week, Barclays noted that if the company were to never grow again, it still would be worth more than its trading at. Morgan Stanley analyst Jay Sole, sees an excellent opportunity to...

Pre-open movers U.S. stock futures traded mostly flat in early pre-market trade, ahead of earnings from Ralph Lauren Corp (NYSE: RL) and CVS Health Corp (NYSE: CVS). Walt Disney Co (NYSE: DIS) and Priceline Group Inc (NASDAQ: PCLN) will release earnings after the closing bell. The Labor Department...